|
Books > Medicine > Clinical & internal medicine > Cardiovascular medicine
|
Buy Now
Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia - Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 (Hardcover, 1990 ed.)
Loot Price: R4,365
Discovery Miles 43 650
|
|
|
Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia - Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 - November 1, 1989 (Hardcover, 1990 ed.)
Series: Developments in Cardiovascular Medicine, 112
Expected to ship within 10 - 15 working days
|
Donate to Against Period Poverty
Total price: R4,385
Discovery Miles: 43 850
|
The Symposium on New Drugs provides for an annual forum for
academic investigators, research and development personnel from the
pharmaceutical and related health care industries, and members of
the Food and Drug Administration to discuss important clinical
research issues. The Tenth Annual Symposium on New Drugs addressed
the problem of whether it was still appropriate to approve
antihypertensive agents soley on the endpoint of lowering cuff
blood pressure. The initial discussions at this symposium related
to the approaches and methods to studying antihypertensive agents.
Dr. William Frishman provided a detailed list of the new approaches
to the treatment of hypertension and pointed out the many new
concepts that are currently active in the development of many new
antihypertensive agents. Dr. William White detailed the growing
importance of ambulatory blood pressure monitoring to define
hypertension and to determine the change in blood pressure due to
pharmacologically active agents. Dr. Jay Cohn pointed out the flaws
in using cuff blood pressure and detailed the potential virtues of
using vascular compliance to identify patients requiring treatment
for hypertension. Dr. Thomas Pickering also discussed the potential
value of evaluating changes in left ventricular hypertrophy a
finding which identifies high risk patients who need to be included
in clinical trials. Dr. Michael Weber detailed the issues and
suggested refinements in the approaches to clinical trial designs
for antihypertensive agents and Dr. Raymond Lipicky discussed the
definition of dose-duration and the role of non-Mem and
Peak/Through measurements in defining an antihypertensive drug
effect.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
